Walter M. Stadler to Phenylurea Compounds
This is a "connection" page, showing publications Walter M. Stadler has written about Phenylurea Compounds.
Connection Strength
1.700
-
Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4.
Score: 0.445
-
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8.
Score: 0.401
-
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
Score: 0.128
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.103
-
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80.
Score: 0.085
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.077
-
Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21.
Score: 0.067
-
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5.
Score: 0.066
-
New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun; 4(6):429-30.
Score: 0.065
-
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
Score: 0.060
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.024
-
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62.
Score: 0.023
-
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
Score: 0.022
-
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7.
Score: 0.022
-
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
Score: 0.021
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.
Score: 0.020
-
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20):3312-8.
Score: 0.020
-
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
Score: 0.018
-
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):125-34.
Score: 0.017
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
Score: 0.016